Cited by 884Cancer-related Molecular PathwaysCancer Genomics and DiagnosticsGenetic factors in colorectal cancer

The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.

TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes

Petitjean, A, Achatz, M I W, Borresen-Dale, A L, Hainaut, P, Olivier, M·2007·Oncogene

Open this paper in CoChat — free account

Abstract

A large amount of data is available on the functional impact of missense mutations in TP53 and on mutation patterns in many different cancers. New data on mutant p53 protein function, cancer phenotype and prognosis have recently been integrated in the International Agency for Research on Cancer TP53 database (http://www-p53.iarc.fr/). Based on these data, we summarize here current knowledge on the respective roles of mutagenesis and biological selection of mutations with specific functional characteristic in shaping the patterns and phenotypes of mutations observed in human cancers. The main conclusion is that intrinsic mutagenicity rates, loss of transactivation activities, and to a lesser extent, dominant-negative activities are the main driving forces that determine TP53 mutation patterns and influence tumor phenotype. In contrast, current experimental data on the acquisition of oncogenic activities (gain of function) by p53 mutants are too scarce and heterogenous to assess whether this property has an impact on tumor development and outcome. In the case of inherited TP53 mutations causing Li-Fraumeni and related syndromes, the age at onset of some tumor types is in direct relation with the degree of loss of transactivation capacity of missense mutations. Finally, studies on large case series demonstrate that TP53 mutations are independent markers of bad prognosis in breast and several other cancers, and that the exact type and position of the mutation influences disease outcome. Further studies are needed to determine how TP53 haplotypes or loss of alleles interact with mutations to modulate their impact on cancer development and prognosis.

Integrity signals

Registry

Crossref · 10.1038/sj.onc.1210302

Cites

117 of 117 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
Sørlie, T., Perou, C. M., Tibshirani, R. J., Aas, T., Geisler, S. B., Johnsen, H., Hastie, T. J., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 11,506
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Surfing the p53 network
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · cited 2×
“191117) encodes a transcription factor which is activated in response to several forms of cellular stress and exerts multiple, antiproliferative functions (Vogelstein et al., 2000).”
Background
Instability and decay of the primary structure of DNA
Lindahl, T. (1993) · Nature · doi:10.1038/362709a0 · Cited by 5,679
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Patterns of somatic mutation in human cancer genomes
Greenman, C. D., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G. R., Davies, H. R., Teague, J. W., Butler, A. P., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,143
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,559

Show all 117 references

Research works printed but not linked: 1

Langerod A, Burdette L, Yeager M, Llaca V, Presswalla S, Gerhard DS et al. (2006a). Pattern of genetic variation in the tp53 locus indicates linkage disequilibrium extends across the flanking genes, ATP1B2 and WDR79. Hum Mutat (in press).

Sorted by citations

Items 501–600 of 883

The Putative Role of TP53 Alterations and p53 Expression in Borderline Ovarian Tumors - Correlation with Clinicopathological Features and Prognosis: A Mini-Review
Semczuk, A., Gogacz, M., Semczuk‐Sikora, A., Jóźwik, M., & Rechberger, T. (2017) · Journal of Cancer · doi:10.7150/jca.19691 · Cited by 13
Relationship between human leukocyte antigen alleles and risk of Kaposi’s sarcoma in Cameroon
Castro, E. M. C., Morrison, B. J., Marshall, V. A., Labò, N., Miley, W., Clements, N., Nelson, G. W., Ndom, P., Stolka, K., Hemingway‐Foday, J., et al. (2019) · Genes and Immunity · doi:10.1038/s41435-019-0077-9 · Cited by 13
Triple-Negative Breast Cancer: Assessing the Role of Immunohistochemical Biomarkers on Neoadjuvant Treatment
da Silva, J. L., Rodrigues, F. R., de Mesquita, G. G., Fernandes, P. V., Thuler, L. C. S., & de Melo, A. C. (2021) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s287320 · Cited by 13
Network cartographs for interpretable visualizations
Hütter, C. V. R., Sin, C., Müller, F., & Menche, J. (2022) · Nature Computational Science · doi:10.1038/s43588-022-00199-z · Cited by 13
Identification of Tissue Types and Gene Mutations From Histopathology Images for Advancing Colorectal Cancer Biology
Jiang, Y., Chan, C. K. W., Chan, R., Wang, X., Wong, N., To, K. F., Ng, S. S. M., Lau, J. Y. W., & Poon, C. C. Y. (2022) · IEEE Open Journal of Engineering in Medicine and Biology · doi:10.1109/ojemb.2022.3192103 · Cited by 14
Associations of MDM2 rs2279744 and TP53 rs1042522 polymorphisms with cervical cancer risk: A meta-analysis and systematic review
Yu, M., Zhang, Q., & Zhao, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.973077 · Cited by 12
p14ARF methylation is a common event in the pathogenesis and progression of myxoid and pleomorphic liposarcoma
Davidović, R. S., Sopta, J. P., Mandušić, V., Krajnović, M., Stanojević, M., Tulić, G., & Dimitrijević, B. (2013) · Medical Oncology · doi:10.1007/s12032-013-0682-9 · Cited by 13
p53 and nasopharyngeal carcinoma: a Malaysian study
Hoe, S., Lee, E. S., Khoo, A. S. B., & Peh, S. C. (2009) · Pathology · doi:10.1080/00313020903071504 · Cited by 13
TP53 codon 72 polymorphism in adult soft tissue sarcomas
Almeida, P. S. R., Manoel, W. J., Reis, Â. A. D. S., Silva, E. R., Martins, E., Paiva, M. V. O., Fraga, A. C., & Saddi, V. A. (2008) · Genetics and Molecular Research · doi:10.4238/vol7-4gmr497 · Cited by 13
Rational Manual and Automated Scoring Thresholds for the Immunohistochemical Detection of TP53 Missense Mutations in Human Breast Carcinomas
Taylor, N. J., Nikolaishvili‐Feinberg, N., Midkiff, B. R., Conway, K., Millikan, R. C., & Geradts, J. (2015) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000207 · Cited by 13
Mechanisms of p53 Functional De-Regulation: Role of the IκB-α/p53 Complex
Carrà, G., Crivellaro, S., Taulli, R., Guerrasio, A., Saglio, G. N., & Morotti, A. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17121997 · Cited by 14
Genetic alterations crossing the borders of distinct hematopoetic lineages and solid tumors: Diagnostic challenges in the era of high-throughput sequencing in hemato-oncology
Shumilov, E., Flach, J., Pabst, T., Fiedler, M., Angelillo‐Scherrer, A., Trümper, L. H. P., Joncourt, R., Kohlmann, A., & Bacher, U. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.03.020 · Cited by 13
The Landscape of the Anti-Kinase Activity of the IDH1 Inhibitors
Malarz, K., Mularski, J., Pacholczyk, M., & Musioł, R. (2020) · Cancers · doi:10.3390/cancers12030536 · Cited by 13
Fuzzy clustering demonstrates that codon 72 SNP rs1042522 of TP53 gene associated with HNSCC but not with prognoses
Pinheiro, U. B., Fraga, C. A. D. C., Mendes, D. C., Farias, L. C., Cardoso, C. M., Silveira, C. M., D’Ângelo, M. F. S. V., Jones, K. M., Santos, S. H. S., de Paula, A. M. B., et al. (2015) · Tumor Biology · doi:10.1007/s13277-015-3677-7 · Cited by 13
A Radiation-Derived Gene Expression Signature Predicts Clinical Outcome for Breast Cancer Patients
Piening, B., Wang, P., Subramanian, A., & Paulovich, A. G. (2009) · Radiation Research · doi:10.1667/rr1223.1 · Cited by 13
Styrylquinazoline derivatives as ABL inhibitors selective for different DFG orientations
Malarz, K., Mularski, J., Pacholczyk, M., & Musioł, R. (2023) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2023.2201410 · Cited by 13
Germline predisposition to myeloid neoplasms: Characteristics and management of high versus variable penetrance disorders
Trottier, A. M., Feurstein, S. K., & Godley, L. A. (2024) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2024.101537 · Cited by 13
Number of rare germline CNVs and TP53 mutation types
Silva, A. G., Achatz, M. I., Krepischi, A. C. V., Pearson, P. L., & Rosenberg, C. (2012) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-7-101 · Cited by 12
Self-citation
A Case of Late-Onset Li-Fraumeni–like Syndrome with Unilateral Breast Cancer
Cho, Y., Kim, J., Kim, Y., Jeong, J., & Lee, K. (2013) · Annals of Laboratory Medicine · doi:10.3343/alm.2013.33.3.212 · Cited by 12
TP53 Arg72Pro polymorphism is associated with increased overall survival but not response to therapy in Portuguese/Caucasian patients with advanced cervical cancer
Coelho, A., Nogueira, A., Soares, S., Assis, J., Pereira, D., Bravo, I., Catarino, R., & Medeiros, R. (2018) · Oncology Letters · doi:10.3892/ol.2018.8354 · Cited by 11
Identification of four serum miRNAs as potential markers to screen for thirteen cancer types
Chen, J. W., & Dhahbi, J. M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0269554 · Cited by 12
TP53 Mutations Are Associated with Increased Infections and Reduced Hematopoietic Cell Transplantation Rates in Myelodysplastic Syndrome and Acute Myeloid Leukemia
Marvin‐Peek, J., Mason, E. F., Kishtagari, A., Jayani, R., Dholaria, B., Kim, T. K., Engelhardt, B. G., Chen, H., Strickland, S. A., Savani, B. N., et al. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.03.008 · Cited by 12
Functional TP53 mutations have no impact on response to cytotoxic agents in metastatic colon cancer
Netter, J., Lehmann‐Che, J., Lambert, J., Tallet, A., Lourenço, N., Soliman, H. R., Bertheau, P., Pariente, B., Chirica, M., Pocard, M. D., et al. (2015) · Bulletin du Cancer · doi:10.1016/j.bulcan.2014.12.010 · Cited by 12
Early onset sebaceous carcinoma
Sung, D., Kaltreider, S. A., & Gonzalez-Fernandez, F. (2011) · Diagnostic Pathology · doi:10.1186/1746-1596-6-81 · Cited by 12
Potential Increase in the Prognostic Value of p53 Mutation by Pro72 Allele in Stage I Non-Small-Cell Lung Cancer
Chien, W.-P., Wong, R., Wu, T.-C., Cheng, Y., Chen, C., & Lee, H. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0495-4 · Cited by 12
HPV infection and p16 INK4A and TP53 expression in rare cancers of the uterine cervix
Missaoui, N., Mestiri, S., Bdioui, A., Zahmoul, T., Hamchi, H., Mokni, M., & Hmissa, S. (2018) · Pathology - Research and Practice · doi:10.1016/j.prp.2018.03.004 · Cited by 12
Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities?
Cavalieri, S., Platini, F., Bergamini, C., Resteghini, C., Galbiati, D., Bossi, P., Perrone, F., Tamborini, E., Quattrone, P., Licitra, L. F., et al. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1598376 · Cited by 12
Immune Infiltration Landscape in Lung Squamous Cell Carcinoma Implications
Zhao, J., Bao, W., & Cai, W. (2020) · BioMed Research International · doi:10.1155/2020/5981870 · Cited by 12
p53, A Victim of the Prion Fashion
Billant, O., Friocourt, G., Roux, P., & Voisset, C. (2021) · Cancers · doi:10.3390/cancers13020269 · Cited by 12
Characteristics and survival of patients with advanced cancer and p53 mutations
Said, R., Ye, Y., Hong, D. S., Jankú, F., Fu, S., Naing, A., Wheler, J. J., Kurzrock, R., Thomas, C. G., Palmer, G. A., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2004 · Cited by 12
Evaluation of heavy metal toxicity in eukaryotes using a simple functional assay
Riger, C. J., Fernandes, P. N., Vilela, L. D. F., Mielniczki-Pereira, A. A., Bonatto, D., Henriques, J. A. P., & Eleuthério, E. C. A. (2011) · Metallomics · doi:10.1039/c1mt00086a · Cited by 12
Association between TP53 R249S mutation and polymorphisms in TP53 intron 1 in hepatocellular carcinoma
Ortiz‐Cuaran, S., Cox, D. G., Villar, S., Friesen, M. D., Durand, G., Chabrier, A., Khuhaprema, T., Sangrajrang, S., Ognjanovic, S., Groopman, J. D., et al. (2013) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22086 · Cited by 12
Self-citation
Genomic instability in the breast microenvironment? A critical evaluation of the evidence
Holliday, C. N., Rummel, S. K., Hooke, J. A., Shriver, C. D., Ellsworth, D. L., & Ellsworth, R. E. (2009) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.09.55 · Cited by 12
Immunohistochemical expression of latent membrane protein 1 (LMP1) and p53 in nasopharyngeal carcinoma: Moroccan experience
Tabyaoui, I., Serhier, Z., Sahraoui, S., Sayd, S., Cadi, R., Bennani, O., Benider, A., Zamiati, S., & Tahiri, J. (2013) · African Health Sciences · doi:10.4314/ahs.v13i3.27 · Cited by 12
The prognostic impact of cigarette smoking on survival in acute myeloid leukemia with TP53 mutations and/or 17p deletions
Bi, X., French, Z., Palmisiano, N. D., Wen, K., & Wilde, L. R. (2022) · Annals of Hematology · doi:10.1007/s00277-022-04812-z · Cited by 11
Insights into Allosteric Mechanisms of the Lung-Enriched p53 Mutants V157F and R158L
Lei, J., Li, X., Cai, M., Guo, T., Lin, D., Deng, X., & Li, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710100 · Cited by 11
Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin
Berge, E. O., Huun, J., Lillehaug, J. R., Lønning, P. E., & Knappskog, S. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2012.12.004 · Cited by 12
Characterization of Novel and Uncharacterized p53 SNPs in the Chinese Population – Intron 2 SNP Co-Segregates with the Common Codon 72 Polymorphism
Phang, B. H., Chua, H. W., Li, H., Linn, Y. C., & Sabapathy, K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0015320 · Cited by 11
Poorer outcome in stromal HIF-2α- and CA9-positive colorectal adenocarcinomas is associated with wild-type TP53 but not with BNIP3 promoter hypermethylation or apoptosis
Cleven, A. H. G., Wouters, B. G., Schütte, B., Spiertz, A. J., van Engeland, M., & de Bruı̈ne, A. P. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604547 · Cited by 11
Association of mRNA expression of TP53 and the TP53 codon 72 Arg/Pro gene polymorphism with colorectal cancer risk in Asian population: a bioinformatics analysis and meta-analysis
Dong, Z., Zheng, L., Liu, W., & Wang, C. (2018) · Cancer Management and Research · doi:10.2147/cmar.s164892 · Cited by 11
Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report
Ma, Y., He, L., Huang, Q., Zheng, S., Zhang, Z., Li, H., & Liu, S. (2018) · BMC Medical Genetics · doi:10.1186/s12881-018-0703-9 · Cited by 11
Identification of the TP53 p.R337H Variant in Tumor Genomic Profiling Should Prompt Consideration of Germline Testing for Li-Fraumeni Syndrome
Sandoval, R. L., Masotti, C., de Macêdo, M. P., Ribeiro, M. F. S. A., Leite, A. C. R., Meireles, S. I., Bovolin, R. M., Santini, F. C., Munhoz, R. R., Jardim, D. L. F., et al. (2021) · JCO Global Oncology · doi:10.1200/go.21.00097 · Cited by 13
Self-citation
Targeted-sequence of normal urothelium and tumor of patients with non-muscle invasive bladder cancer
Hayashi, Y., Fujita, K., Sakai, K., Adomi, S., Banno, E., Nojima, S., Tomiyama, E., Matsushita, M., Kato, T., Hatano, K., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-21158-8 · Cited by 12
DN‐R175H p53 mutation is more effective than p53 interference in inducing epithelial disorganization and activation of proliferation signals in human carcinoma cells: Role of E‐cadherin
Rieber, M., & Rieber, M. S. (2009) · International Journal of Cancer · doi:10.1002/ijc.24512 · Cited by 11
Virilizing adrenocortical carcinoma in a child with Turner syndrome and somatic TP53 gene mutation
Ko, J.-H., Lee, H. S., Hong, J. S., & Hwang, J. S. (2009) · European Journal of Pediatrics · doi:10.1007/s00431-009-1051-8 · Cited by 11
Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups
van den Broek, A. J., Broeks, A., Horlings, H. M., Canisius, S., Braaf, L. M., Langerød, A., Veer, L. J. V., & Schmidt, M. K. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1615-y · Cited by 11
The aberrant asynchronous replication — characterizing lymphocytes of cancer patients — is erased following stem cell transplantation
Nagler, A., Cytron, S., Mashevich, M., Korenstein-Ilan, A., & Avivi, L. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-230 · Cited by 11
The tumour‐suppressor p53 is not required for pancreatic β cell death during diabetes and upon irradiation
Nam, S. Y., Lee, M. K., & Sabapathy, K. (2007) · The Journal of Physiology · doi:10.1113/jphysiol.2007.142612 · Cited by 11
Master regulator: p53’s pivotal role in steering NK-cell tumor patrol
Wang, H., Chen, Q., Liu, Q., & Luo, C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1428653 · Cited by 11
Prognostic implications of securin expression and sub-cellular localization in human breast cancer
Gurvits, N., Repo, H., Löyttyniemi, E., Nykänen, M., Anttinen, J., Kuopio, T., Talvinen, K., & Kronqvist, P. (2016) · Cellular Oncology · doi:10.1007/s13402-016-0277-5 · Cited by 10
An Ensemble Strategy to Predict Prognosis in Ovarian Cancer Based on Gene Modules
Gao, Y., Zhou, X., & Zhang, W. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00366 · Cited by 10
Dissociation Pathways of the p53 DNA Binding Domain from DNA and Critical Roles of Key Residues Elucidated by dPaCS-MD/MSM
Sobeh, M., & Kitao, A. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c01508 · Cited by 11
Novel p53 splicing site mutation in Li‐Fraumeni‐like syndrome with osteosarcoma
Sakurai, N., Iwamoto, S., Miura, Y., Nakamura, T., Matsumine, A., Nishioka, J., Nakatani, K., & Komada, Y. (2013) · Pediatrics International · doi:10.1111/j.1442-200x.2012.03641.x · Cited by 10
Decrease of mitochondrial p53 during late apoptosis is linked to its dephosphorylation on serine 20
Castrogiovanni, C., Vandaudenard, M., Waterschoot, B., Backer, O. D., & Dumont, P. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1070978 · Cited by 11
New recurrent deletions in the PPARγ and TP53 genes are associated with childhood myelodysplastic syndrome
Silveira, C. G. T., de Oliveira, F. M., Valera, E. T., Ikoma, M. R. V., Borgonovo, T., Cavalli, I. J., Tone, L. G., & Rogatto, S. R. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.07.013 · Cited by 10
Inferring Gene Dependency Network Specific to Phenotypic Alteration Based on Gene Expression Data and Clinical Information of Breast Cancer
Zhou, X., & Liu, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092023 · Cited by 10
The status of p53 in cancer cells affects the role of autophagy in tumor radiosensitisation.
Zheng, R., Yao, Q., Du, S., Ren, C., Sun, Q., Xu, Z., Lin, X., & Yuan, Y. (2014) · PubMed · Cited by 10
p53 in the Clinics
Hainaut, P. L., Wiman, K. G., & Olivier, M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3676-8 · Cited by 10
Self-citation
Association of p53 Codon 72 Polymorphism with Breast Cancer in a Rwandese Population
Habyarimana, T., Attaleb, M., Mugenzi, P., Mazarati, J. B., Bakri, Y., & Mzibri, M. E. (2017) · Pathobiology · doi:10.1159/000481664 · Cited by 10
Detection of a novel, primate-specific ‘kill switch’ tumor suppression mechanism that may fundamentally control cancer risk in humans: an unexpected twist in the basic biology of TP53
Nyce, J. W. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0241 · Cited by 10
Protein interaction disruption in cancer
Ruffalo, M., & Bar‐Joseph, Z. (2019) · BMC Cancer · doi:10.1186/s12885-019-5532-5 · Cited by 10
Estimating the Frequency of Single Point Driver Mutations across Common Solid Tumours
Darbyshire, M., du Toit, Z. D., Rogers, M. F., Gaunt, T. R., & Campbell, C. (2019) · Scientific Reports · doi:10.1038/s41598-019-48765-2 · Cited by 10
Prognostic significance of the tumor suppressor protein p53 gene in childhood acute lymphoblastic leukemia
Weng, W., Zhang, P., Ruan, J., Zhang, Y., Ba, D., & Tang, Y. (2019) · Oncology Letters · doi:10.3892/ol.2019.11064 · Cited by 10
Mutations in TP53 and PIK3CA genes in hepatocellular carcinoma patients are associated with chronic Schistosomiasis
AlGabbani, Q. (2021) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2021.10.022 · Cited by 10
Gaining insights into relevance across cancers based on mutation features of TP53 gene
Mei, Y., Liang, D., Wang, T., & Yu, D. S. (2021) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2021.101165 · Cited by 10
The gene expression signature associated with TP 53 mutation/deletion in chronic lymphocytic leukaemia is dominated by the under‐expression of TP 53 and other genes on chromosome 17p
Lin, K., Lane, B. S., Carter, A., Johnson, G. G., Onwuazor, O. N., Oates, M., Zenz, T., Stilgenbauer, S., Atherton, M., Douglas, A., et al. (2012) · British Journal of Haematology · doi:10.1111/bjh.12092 · Cited by 11
Mutant p53 protein expression and antioxidant status deficiency in breast cancer
Milićević, Z., Kasapović, J., Gavrilović, L., Milovanović, Z., Bajić, V., & Spremo‐Potparević, B. (2014) · Europe PMC (PubMed Central) · doi:10.17877/de290r-6859 · Cited by 10
TP53 codon 72 polymorphism may predict early tumour progression in paediatric pilocytic astrocytoma
Mascelli, S., Nozza, P., Jones, D., Colin, C., Pistorio, A., Milanaccio, C., Ravegnani, M., Consales, A., Witt, O., Morana, G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10295 · Cited by 10
MCDHGN: heterogeneous network-based cancer driver gene prediction and interpretability analysis
Wang, L., Zhou, J., Wang, X., Wang, Y., & Li, J. (2024) · Bioinformatics · doi:10.1093/bioinformatics/btae362 · Cited by 9
Activity-based selection for enhanced base editor mutational scanning
Kaplan, E. L., Steger, R. J., Shah, S. T., Drepanos, L. M., Griffith, A. L., Reint, G., & Doench, J. G. (2025) · Nature Genetics · doi:10.1038/s41588-025-02366-0 · Cited by 9
Activation of p53 for the treatment of cancer
Chen, J., & Huang, X. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22187 · Cited by 9
Multimodality MRI radiomics analysis of TP53 mutations in triple negative breast cancer
Sun, K., Zhu, H., Chai, W., & Yan, F. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1153261 · Cited by 9
Defining function of wild-type and three patient-specific TP53 mutations in a zebrafish model of embryonal rhabdomyosarcoma
Chen, J., Baxi, K., Lipsitt, A. E., Hensch, N. R., Wang, L., Sreenivas, P., Modi, P. S., Zhao, X. R., Baudin, A., Robledo, D. G., et al. (2023) · eLife · doi:10.7554/elife.68221 · Cited by 9
The roles of anti-Müllerian hormone in breast cancer
Chen, X., Liu, S., Peng, X., & Zong, X. (2023) · Endocrine Related Cancer · doi:10.1530/erc-23-0060 · Cited by 10
A machine learning and directed network optimization approach to uncover TP53 regulatory patterns
Triantafyllidis, C. P., Barberis, A., Hartley, F., Miar, A., Gjerga, E., Charlton, P. V., van Bijsterveldt, L., Sáez-Rodríguez, J., & Buffa, F. M. (2023) · iScience · doi:10.1016/j.isci.2023.108291 · Cited by 9
Role of p53 Pathway Alterations in Uterine Carcinosarcomas (Malignant Mixed Müllerian Tumors)
Semczuk, A., Ignatov, A., Obrzut, B., Reventós, J., & Rechberger, T. (2014) · Oncology · doi:10.1159/000363574 · Cited by 9
Transitions at CpG Dinucleotides, Geographic Clustering of TP53 Mutations and Food Availability Patterns in Colorectal Cancer
Verginelli, F., Bishehsari, F., Napolitano, F., Mahdavinia, M., Cama, A., Malekzadeh, R., Miele, G., Raiconi, G., Tagliaferri, R., & Mariani‐Costantini, R. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006824 · Cited by 9
SARS-CoV-2 Vaccination and the Multi-Hit Hypothesis of Oncogenesis
Angues, R. V., & Bustos, Y. P. (2023) · Cureus · doi:10.7759/cureus.50703 · Cited by 11
Clinicopathologic Characteristics of Brain Tumors are Associated with the Presence and Patterns of TP53 Mutations: Evidence from the IARC TP53 Database
Salnikova, L. E. (2014) · NeuroMolecular Medicine · doi:10.1007/s12017-014-8290-1 · Cited by 9
IFI16 mis-localization can be a contributing factor to hepatocellular carcinoma progression
Shi, X., Liu, J., Liu, Q., & Li, M. (2014) · Medical Hypotheses · doi:10.1016/j.mehy.2014.01.017 · Cited by 9
Assessment of p53 mutations, expression and prognosis in bladder cancer patients from Jordan: Identification of novel deletion mutations in the DNA-binding domain
Bodoor, K., Al‐Ghabkari, A., Matalka, I. I., Haddad, Y., Alkhateeb, A. M., Jaradat, S. A., Jaradat, Z. W., Al-Ghazo, M. A., Abu-sheikha, A., Jalboush, S. A., et al. (2017) · Meta Gene · doi:10.1016/j.mgene.2017.01.002 · Cited by 9
p53: It Has It All, But Will It Make It to the Clinic As a Marker in Bladder Cancer?
Real, F. X. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1904 · Cited by 9
TP53 as clinical marker in head and neck cancer
Peltonen, J. K. (2011) · Cited by 9
Impact of TP53 gene variants on prognosis and survival of childhood acute lymphoblastic leukemia
Fırtına, S., Erbilgin, Y., Ng, Ö. H., Karaman, S., Karakaş, Z., Celkan, T. T., Gelen, S. A., Yildirmak, Y., Özbek, U., & Sayitoğlu, M. (2023) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2023.2195682 · Cited by 8
A Review: Genetic Mutations as a Key to Unlocking Drug Resistance in Cervical Cancer
Eksteen, C., Riedemann, J., Rass, A., du Plessis, M., Botha, M. H., der Merwe, F. H. V., & Engelbrecht, A. (2024) · Cancer Control · doi:10.1177/10732748241261539 · Cited by 8
AI-Driven Multiscale Study on the Mechanism of Polygonati Rhizoma in Regulating Immune Function in STAD
Yang, P., Wang, X., Yang, J., Yan, B., Sheng, H., Li, Y., Yang, Y., & Wang, J. (2025) · ACS Omega · doi:10.1021/acsomega.5c00981 · Cited by 8
Structural dynamics of the wild-type p53 DNA-binding domain and hotspot mutants reveal oncogenic conformational shifts
Zhao, Z., Wang, G., Wu, X., & Qian, Z. (2025) · Physical Chemistry Chemical Physics · doi:10.1039/d5cp01257k · Cited by 8
Germline Predisposition to Myeloid Neoplasms
Obiorah, I. E., Upadhyaya, K., & Calvo, K. R. (2023) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2023.06.004 · Cited by 8
Che-1 gene silencing induces osteosarcoma cell apoptosis by inhibiting mutant p53 expression
Liu, M., Wang, D., & Li, N. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.03.073 · Cited by 8
C/EBPβ suppresses keratinocyte autonomous type 1 IFN response and p53 to increase cell survival and susceptibility to UVB-induced skin cancer
Tam, H. W., Hall, J. R., Messenger, Z. J., Jima, D. D., House, J. S., Linder, K. E., & Smart, R. C. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz012 · Cited by 7
Chloroquine induces transitory attenuation of proliferation of human lung cancer cells through regulation of mutant P53 and YAP
Saini, H., Choudhary, M., Sharma, H., Chowdhury, S., Mukherjee, S., & Chowdhury, R. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-08072-y · Cited by 8
Whole-exome sequencing reveals mutational profiles of anorectal and gynecological melanoma
Sun, W., Liu, K., Zhou, H., Zhao, F., Dong, Y., Xu, Y., Kong, Y., Wang, M., Cheng, X., & Chen, Y. (2023) · Medical Oncology · doi:10.1007/s12032-023-02192-6 · Cited by 8
The TP53 gene polymorphisms and survival of sporadic breast cancer patients
Bišof, V., Salihović, M. P., Narančić, N. S., Škarić‐Jurić, T., Jakić‐Razumović, J., Janičijević, B., & Rudan, P. (2011) · Medical Oncology · doi:10.1007/s12032-011-9875-2 · Cited by 8
Measuring Minimal Residual Disease in Chronic Myeloid Leukemia: Fluorescence In Situ Hybridization and Polymerase Chain Reaction
Hughes, T. P., & Branford, S. (2009) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2009.s.022 · Cited by 8
Analysis of Chromosome 17 miRNAs and Their Importance in Medulloblastomas
López-Ochoa, S., Ramírez-García, M., Castro-Sierra, E., & Arenas‐Huertero, F. (2015) · BioMed Research International · doi:10.1155/2015/717509 · Cited by 8
Functional studies of a novel Germline p53 splicing mutation identified in a patient with Li– F raumeni‐ L ike syndrome
Piao, J., Sakurai, N., Iwamoto, S., Nishioka, J., Nakatani, K., Komada, Y., Mizutani, S., & Takagi, M. (2012) · Molecular Carcinogenesis · doi:10.1002/mc.21912 · Cited by 7
Detección de aneuploidías del cromosoma 17 y deleción del gen TP53 en una amplia variedad de tumores sólidos mediante hibridación in situ fluorescente bicolor
Herrera, J. C., Isaza, L. F., Ramírez, J. L., Vásquez, G., & Peña, C. M. M. (2010) · Biomédica · doi:10.7705/biomedica.v30i3.273 · Cited by 8
Ranking the Binding Energies of p53 Mutant Activators and Their ADMET Properties
Omar, S. I., & Tuszyński, J. A. (2014) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12480 · Cited by 8
A novel TP53 germline inframe deletion identified in a Spanish series of Li-fraumeni syndrome suspected families
Llovet, P., Illana, F. J., Martín-Morales, L., de la Hoya, M., Garré, P., Ibañez-Royo, M. D., Pérez‐Segura, P., Caldés, T., & García‐Barberán, V. (2017) · Familial Cancer · doi:10.1007/s10689-017-9990-0 · Cited by 8
Cancerouspdomains: comprehensive analysis of cancer type-specific recurrent somatic mutations in proteins and domains
Hashemi, S., Dalini, A. N., Jalali, A., Banaei‐Moghaddam, A. M., & Razaghi‐Moghadam, Z. (2017) · BMC Bioinformatics · doi:10.1186/s12859-017-1779-5 · Cited by 8

Authors: Petitjean, A., Achatz, M. I. W., Borresen-Dale, A. L., Hainaut, P., & Olivier, M.
Affiliations: Centre international de recherche sur le cancer (FR)
Corresponding author: Hainaut, P
ORCID: Petitjean, A
Achatz, M I W
Hainaut, P
Olivier, M
Venue: Oncogene
Publisher: Springer Science and Business Media LLC
Published: 2007-04-02
Volume: 26
Issue: 15
Pages: 2157-2165
ISSN: 0950-9232 (ISSN-L)
1476-5594
DOI: 10.1038/sj.onc.1210302
OpenAlex: W2042484101
Cited by: 884
References: 117
Citations by year: 2026: 16 · 2025: 29 · 2024: 29 · 2023: 50 · 2022: 55 · 2021: 52 · 2020: 50 · 2019: 53 · 2018: 60 · 2017: 46 · 2016: 57 · 2015: 52 · 2014: 53 · 2013: 43 · 2012: 48
FWCI: 5.08
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Oncogene (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords: TP53 mutation, missense mutations, dominant-negative p53, gain-of-function, mutagenesis, tumor phenotype, cancer prognosis, Li-Fraumeni syndrome, loss of heterozygosity, breast cancer
MeSH terms: Genetic Markers, Humans, Mutation, Neoplasms, Polymorphism, Genetic, Prognosis, Biomarkers, Tumor, Tumor Suppressor Protein p53, Mutagenesis, Li-Fraumeni Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks